Bellicum Pharmaceuticals Inc. (BLCM) 28.55 $BLCM
Juno Therapeutics Gets Lift From Cancer Test Results
at Investor's Business Daily - Tue Apr 21, 1:57PM CDT
Juno Therapeutics' (JUNO) stock rebounded Tuesday as the company reported "highly encouraging" results from a clinical trial on pediatric patients with leukemia, after shares fell sharply Monday. Juno is developing cellular immunotherapies to treat...
BLCM: 28.55 (+2.59), KITE: 57.56 (-1.43), JUNO: 55.72 (-0.68), NVS: 103.45 (-0.62)
Juno, Kite CAR-T Stocks Fall on Disappointing Solid Tumor Data
at The Street - Mon Apr 20, 9:22AM CDT
Shares of Juno Therapeutics and Kite Pharma are weak Monday following a lackluster showing for so-called CAR-T cellular therapies in solid tumors at a closely watched cancer conference this weekend.
ZIOP: 10.88 (+0.03), BLCM: 28.55 (+2.59), KITE: 57.56 (-1.43), JUNO: 55.72 (-0.68)
Heat Biologics Is An Opportunity Among Soaring Immunotherapy Biotech Valuations
Sharon di Stefano - Seeking Alpha - Tue Apr 14, 8:20AM CDT
Vaccination, in medical terminology, is injection of a disease-causing microorganism that stimulates the immune system to fight against infection, using the body's own defense mechanisms. Vaccination has all but wiped out polio, tetanus, chicken pox...
HTBX: 7.71 (-0.64), BLCM: 28.55 (+2.59), KITE: 57.56 (-1.43), PFE: 34.93 (+0.04), MRK: 57.69 (+0.03), CLLS: 31.30 (-0.91), SPPI: 5.98 (+0.04), JUNO: 55.72 (-0.68), BMY: 66.60 (-0.21)
Global & USA Cancer Immunotherapy Market Analysis 2015-2020
M2 - Fri Apr 10, 5:22AM CDT
Research and Markets (http://www.researchandmarkets.com/research/z6tkxf/global_and_usa) has announced the addition of the "GLOBAL & USA CANCER IMMUNOTHERAPY MARKET ANALYSIS TO 2020: Antibody Drug Conjugates (ADCs), Bispecific Monoclonal Antibodies, Cancer Vaccines, Cytokines, Interferons, Chimeric Antigen Receptor (CAR) T-Cell Therapy, PD-1/PD-L1 inhibitors, Dendritic Cells, Checkpoint Inhibitors, Adopted Cell Therapy (ACT) & IDO Inhibitors" report to their offering. Cancer immunotherapy drugs have captured nearly 50% of the overall oncology drugs market, generating about $41.0 billion in 2014 alone This report provides a comprehensive overview of the size of cancer immunotherapy market, the segmentation of the market, key players and the vast potential of therapies that are in clinical trials. Oncologic therapeutics cannot cure cancer and yet in 2014, the overall market for cancer therapeutics stood at about $84.3 billion. Any drug that can provide a reasonable survival of more than five years for the cancer patients can achieve a blockbuster status. Within the cancer therapeutics, the immunotherapeutic drugs have gained worldwide acceptance, because they are targeted drugs targeting only the cancer cells. Scope - An overview of cancer immunotherapy that includes: monoclonal antibodies, cancer vaccines and non-specific cancer immunotherapies. - Focus on current trends in cancer immunotherapies that include: anti-PD-1 drugs, Dendritic cell vaccines, T-cell therapies and cancer vaccines. - Insight into the challenges faced by drug developers, particularly about the success vs. failure ratios in developing cancer immunotherapy drugs. - Descriptions about 23 cancer immunotherapeutics approved and used as targeted drugs (some of these products have already been withdrawn from the market). - Insight into the various immunotherapeutics available for specific cancer types. - Description and data for the prevalence of cancer types that are addressed by cancer immunotherapeutics. - Overall global cancer therapeutics market, leading market players and the bestselling cancer drugs. - Detailed account of the market for cancer immunotherapeutics by geography, indication, company and individual drugs. - Profiles, marketed products and products in pipeline of 76 companies that are mostly located in the U.S. and Europe. - Summary table to identify the category of immunotherapy drug offered by the 76 companies. Companies Mentioned - 30 of the 75 Companies Featured - Ablynx NV - Activartis Biotech GmbH - Advaxis Inc. - Aduro BioTech Inc. - Agenus Inc. - AlphaVax Inc. - Amgen Inc. - Antigen Express Inc. - Argos Therapeutics Inc. - Bavarian Nordic A/S - Bellicum Pharmaceuticals Inc. - Biogen Idec Inc.x - Biovest International Inc. - Genmab AS - GlaxoSmithKline - Gliknik Inc. - GlobeImmune Inc. - Heat Biologics Inc. - Immatics Biotechnologies GmbH - ImmunoCellular Therapeutics Ltd. - Merrimack Pharmaceuticals Inc. - Morphotek Inc. - NewLink Genetics Corp. - Northwest Biotherapeutics Inc. - NovaRx Corp. - OncoPep Inc. - Oncothyreon Inc. - OSE Pharma SA - Viventia Biotechnologies Inc. - Wilex AG For more information visit http://www.researchandmarkets.com/research/z6...al_and_usa
HTBX: 7.71 (-0.64), BIIB: 423.57 (+1.46), NWBO: 8.36 (-0.39), ADXS: 22.18 (+0.10), ADRO: 38.17 (-0.50), AMGN: 169.10 (+0.64), GSK: 46.57 (-0.67), ONTY: 1.80 (+0.03), IMUC: 0.53 (+0.02), MACK: 13.44 (+0.18), GBIM: 8.46 (+0.46), ARGS: 8.48 (-0.11), BLCM: 28.55 (+2.59), NLNK: 53.12 (-0.07)
BUYINS.NET: BLCM SqueezeTrigger Price is $23.85. There is $19,639,166 That Short Sellers Still Need To Cover.
M2 - Wed Apr 08, 4:42AM CDT
BUYINS.NET / www.squeezetrigger.com is monitoring BAILIE COMMUNUCATION (NASDAQ:BLCM) in real time and just received an alert that BLCM is crossing above its primary SqueezeTrigger Price, the price that a short squeeze can start in any stock. There are 823100 shares that have been shorted at the volume weighted average SqueezeTrigger Price of $23.85. To access SqueezeTrigger Prices ahead of potential short squeezes beginning, visit http://www.squeezetrigger.com .
BLCM: 28.55 (+2.59)
Another IPO Filed In Hot Cancer Immunotherapy Field
at Investor's Business Daily - Tue Apr 07, 12:55PM CDT
Adaptimmune Therapeutics has filed for an initial public offering, adding another company to one of the hottest sectors in the biotech field. U.K.-based Adaptimmune Therapeutics plans to raise up to $150 million and list on the Nasdaq under the...
BLUE: 136.49 (+1.22), BLCM: 28.55 (+2.59), KITE: 57.56 (-1.43), AMGN: 169.10 (+0.64), JUNO: 55.72 (-0.68)
This Small Biotech Got A Booster Shot On CAR-T Deal
at Investor's Business Daily - Mon Mar 30, 1:15PM CDT
Shares of Intrexon (XON) gapped up on news that the synthetic biotech had formed a collaboration and licensing deal with biopharmaceutical firm Merck KGaA of Darmstadt, Germany, to develop and commercialize CAR-T therapies. Intrexon shares rose 9% to...
ZIOP: 10.88 (+0.03), BLCM: 28.55 (+2.59), KITE: 57.56 (-1.43), MRK: 57.69 (+0.03), CLLS: 31.30 (-0.91), XON: 44.53 (+0.36), AMGN: 169.10 (+0.64), JUNO: 55.72 (-0.68)
Intrexon and Merck Serono team up in cancer immunotherapy
Seeking Alpha - at Seeking Alpha - Mon Mar 30, 8:05AM CDT
BLUE: 136.49 (+1.22), BLCM: 28.55 (+2.59), KITE: 57.56 (-1.43), XON: 44.53 (+0.36), JUNO: 55.72 (-0.68)
IPO Stock Watch: CAR-T Maker Cellectis Slips In Debut
at Investor's Business Daily - Wed Mar 25, 3:59PM CDT
French biotech Cellectis (CLLS) slipped 5.3% in its Nasdaq debut Wednesday to close at 39.30 after enlarging its deal size to $229 million. Cellectis sold 5.5 million shares at $41.50 each, the price being essentially determined by where the stock...
BLCM: 28.55 (+2.59), KITE: 57.56 (-1.43), PFE: 34.93 (+0.04), CLLS: 31.30 (-0.91), JUNO: 55.72 (-0.68)
Bellicum Pharmaceuticals, Inc. (BLCM) in Focus: Stock Jumps 6.1% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Mar 20, 8:18AM CDT
Bellicum Pharmaceuticals, Inc. (BLCM) was a big mover last session, as the company saw its shares rise over 6% on the day.
EARS: 4.65 (-0.75), BLCM: 28.55 (+2.59)
Biotech Stock Mailbag: Breaking the Feuerstein-Ratain Rule; Medical Conferences; Celgene
at The Street - Fri Mar 20, 6:18AM CDT
Biotech columnist Adam Feuerstein answers readers' questions about health care companies.
BIIB: 423.57 (+1.46), ACT: 295.22 (+0.69), OVAS: 29.85 (-0.24), RGLS: 17.40 (-0.22), CTIC: 1.93 (+0.09), CELG: 115.54 (+0.72), BLCM: 28.55 (+2.59), GILD: 104.18 (-1.02), KITE: 57.56 (-1.43), MRK: 57.69 (+0.03), RCPT: 166.76 (-3.37), JUNO: 55.72 (-0.68), NVS: 103.45 (-0.62)
Coronado's Latest Opportunistic Move: CAR-T Therapy
EP Vantage - Seeking Alpha - Thu Mar 19, 2:03PM CDT
Give Coronado Biosciences ’ (NASDAQ: CNDO ) management team top marks for brazen opportunism. After seeing its porcine whipworm egg-based project fail in Crohn's disease, the group is getting into some of biotech's hottest areas, earlier this...
BLCM: 28.55 (+2.59), CNDO: 4.09 (-0.09), CLLS: 31.30 (-0.91)
Juno Therapeutics Comments On Cancer Cure Lifts Group
at Investor's Business Daily - Thu Mar 19, 1:36PM CDT
Enthusiasm about potential cancer cures sent shares of Juno Therapeutics (JUNO) and its peers flying Thursday, though Juno's fourth-quarter earnings late Wednesday missed Wall Street estimates by a lot. "Within the next 12 months, we expect to have...
BLUE: 136.49 (+1.22), BLCM: 28.55 (+2.59), KITE: 57.56 (-1.43), AMGN: 169.10 (+0.64), JUNO: 55.72 (-0.68), NVS: 103.45 (-0.62)
CAR-T cancer therapy stocks head north
Seeking Alpha - at Seeking Alpha - Thu Mar 19, 12:29PM CDT
BLUE: 136.49 (+1.22), ZIOP: 10.88 (+0.03), BLCM: 28.55 (+2.59), KITE: 57.56 (-1.43), CNDO: 4.09 (-0.09), CLLS: 31.30 (-0.91), JUNO: 55.72 (-0.68)
Engineered TCR and CAR Immunotherapeutics Analysis Report 2015
M2 - Thu Mar 19, 12:08PM CDT
Research and Markets (http://www.researchandmarkets.com/research/mvztx7/engineered_tcr) has announced the addition of the "Engineered TCR and CAR Immunotherapeutics 2015" report to their offering. This report Engineered TCR and CAR Immunotherapeutics 2015: A comparative analysis of the landscape of and business opportunities with TCR and CAR antibodies, T cells, NK cells, TILs, DLIs & DLIs as of March 2015 brings you up-to-date regarding key players, key technologies, TCR and CAR immunotherapeutic projects, business deals and private and public financing rounds. The report analyzes the TCR and CAR immunotherapeutic pipelines and stakeholders in the field, especially among Big Pharma/Biotech and technology companies. The report highlights the value of TCR and CAR immunotherapeutics in terms of partnering economic conditions, private financing rounds and (initial) public offerings with the resulting market capitalization of companies. However, progress in clinical trials and supply of clinical grade batches reveals some major limitations which need to be surmounted and the problems solved if TCR and CAR immunotherapeutics want to become commercially viable and successful products. This report describes the challenges and limitations and identifies solutions provided by new technologies which offer tremendous business opportunities. This report has been built in a bottom-up basis by desktop search to identify and describe company, product, technology and business/financing profiles which then are evaluated and analyzed with a final outlook describing perspectives with challenges and opportunities. What will you find in the report? - Profiles of TCR and CAR immunotherapeutics in development - Competitor analysis of CD19 CAR T cells - Options to improve CAR T cells regarding efficacy, safety, manufacturing and commercial value - Target analysis of TCR T cells in R&D - CAR T Cell pipeline in hematology - CAR T Cell pipeline in solid tumors - Allogeneic TCR and CAR T cells in R&D - Universal antibody-targeted CAR T cells and NK cells - Pipeline of most promising TILs, NK cells, DLIs and CTLs - Technologies needed for next generations of TCR and CAR immunotherapeutics - Profiles of biotechnology companies incl. financing and licensing/partnering - Profiles and scope of interest of Big Pharma/Biotech companies for TCRs & CARs - Stakeholder analysis (established, emerging, non-US, technology providing companies) - Potential of alternative adoptive immunotherapies with NK cells, TILs, CTLs and DLIs - Analysis of major partnering deals between Big pharma and technology companies - Economic terms of pharma-biotech deals - Opportunities for biotech-biotech deals in the TCR and CAR field - Potential to raise private money with TCR and CAR technologies - Success in initial public offerings and follow on offerings with TCRs and CARs - Limitations and hurdles with current TCR and CAR immunotherapeutics - Opportunities for novel TCR and CAR immunotherapeutics - Pricing of TCR and CAR immunotherapeutics - Aspects of manufacturing and commercialization Who will benefit from the report? - Venture capital, private equity and investment managers - Financial analysts - CFO - Business development and licensing (BDL) specialists - Marketing managers - CEO, COO and managing directors - Corporate strategy, product and portfolio analysts and managers - Chief Technology Officer - Cell technology and manufacturing specialists - Clinical and preclinical development specialists Key Topics Covered: 1 Introduction 2 Executive Summary 3 Profiles of TCR & CAR Immunotherapeutics, NK Cells, TILs, DLIs and CTLs 4 Pipeline Analysis 5 Technology Companies 6 Pharmaceutical Companies 7 Stakeholder Analysis 8 Selected Technology Profiles 9 Business Perspective on TCR and CAR Immunotherapeutics 10 Outlook for TCR and CAR Immunotherapeutics Companies Mentioned - Adaptimmune - Altor Biosciences - Amgen - Applied Immune Technologies - AstraZeneca - Autolus - Bellicum Pharmaceuticals - Bluebird bio - Cardio3 BioSciences - Celgene - Conkwest - CRISPR Therapeutics - CytomX - Editas Medicine - Eli Lilly - Eureka Therapeutics - GlaxoSmithKline - Immunocore - Intellia Therapeutics - Intrexon - Janssen (J&J) - Juno Therapeutics - Kite Pharma - Lion Biotechnologies - Medigene - Nextera - Novartis - Pfizer - Roche - Servier For more information visit http://www.researchandmarkets.com/research/mv...neered_tcr
BLCM: 28.55 (+2.59), KITE: 57.56 (-1.43), AMGN: 169.10 (+0.64), LBIO: 12.50 (+0.50), JUNO: 55.72 (-0.68), LLY: 72.30 (+0.09), GSK: 46.57 (-0.67), NVS: 103.45 (-0.62), CELGZ: 2.87 (+0.04)
Hot Biotech Juno Therapeutics Burning Through Cash
at Investor's Business Daily - Wed Mar 18, 7:22PM CDT
Juno Therapeutics (JUNO), which set a record as the most highly valued biotech IPO of 2014, reported fourth quarter earnings late Wednesday that missed Wall Street estimates by a wide margin. Juno is developing cellular immunotherapies to treat...
BLCM: 28.55 (+2.59), KITE: 57.56 (-1.43), PFE: 34.93 (+0.04), AMGN: 169.10 (+0.64), JUNO: 55.72 (-0.68)
Medigene AG: Addressing The CAR-T Market Pain Points
Decision Analytics - Seeking Alpha - Wed Mar 18, 11:51AM CDT
I have written about the market opportunity for adoptive cancer immunotherapy before when my interest was piqued by the incredible appreciation of a number of early-stage CAR-T therapy companies (a form of adoptive immunotherapy). Companies such as...
MDVN: 128.88 (+0.29), JNJ: 100.43 (+0.13), ZIOP: 10.88 (+0.03), BLCM: 28.55 (+2.59), KITE: 57.56 (-1.43), JUNO: 55.72 (-0.68), NVS: 103.45 (-0.62)
Cellectis on deck for what should be a very strong IPO
Seeking Alpha - at Seeking Alpha - Wed Mar 18, 9:42AM CDT
BLUE: 136.49 (+1.22), BLCM: 28.55 (+2.59), KITE: 57.56 (-1.43), PFE: 34.93 (+0.04), CLLS: 31.30 (-0.91), JUNO: 55.72 (-0.68)
Bellicum Pharmaceuticals EPS of -$18.99
Seeking Alpha - at Seeking Alpha - Wed Mar 11, 3:12PM CDT
BLCM: 28.55 (+2.59)
Juno Therapeutics Gets Lift From Cancer Test Results
at Investor's Business Daily - Tue Apr 21, 1:57PM CDT
Juno Therapeutics' (JUNO) stock rebounded Tuesday as the company reported "highly encouraging" results from a clinical trial on pediatric patients with leukemia, after shares fell sharply Monday. Juno is developing cellular immunotherapies to treat...
BLCM: 28.55 (+2.59), KITE: 57.56 (-1.43), JUNO: 55.72 (-0.68), NVS: 103.45 (-0.62)
Juno, Kite CAR-T Stocks Fall on Disappointing Solid Tumor Data
at The Street - Mon Apr 20, 9:22AM CDT
Shares of Juno Therapeutics and Kite Pharma are weak Monday following a lackluster showing for so-called CAR-T cellular therapies in solid tumors at a closely watched cancer conference this weekend.
ZIOP: 10.88 (+0.03), BLCM: 28.55 (+2.59), KITE: 57.56 (-1.43), JUNO: 55.72 (-0.68)
Heat Biologics Is An Opportunity Among Soaring Immunotherapy Biotech Valuations
Sharon di Stefano - Seeking Alpha - Tue Apr 14, 8:20AM CDT
Vaccination, in medical terminology, is injection of a disease-causing microorganism that stimulates the immune system to fight against infection, using the body's own defense mechanisms. Vaccination has all but wiped out polio, tetanus, chicken pox...
HTBX: 7.71 (-0.64), BLCM: 28.55 (+2.59), KITE: 57.56 (-1.43), PFE: 34.93 (+0.04), MRK: 57.69 (+0.03), CLLS: 31.30 (-0.91), SPPI: 5.98 (+0.04), JUNO: 55.72 (-0.68), BMY: 66.60 (-0.21)
Global & USA Cancer Immunotherapy Market Analysis 2015-2020
M2 - Fri Apr 10, 5:22AM CDT
Research and Markets (http://www.researchandmarkets.com/research/z6tkxf/global_and_usa) has announced the addition of the "GLOBAL & USA CANCER IMMUNOTHERAPY MARKET ANALYSIS TO 2020: Antibody Drug Conjugates (ADCs), Bispecific Monoclonal Antibodies, Cancer Vaccines, Cytokines, Interferons, Chimeric Antigen Receptor (CAR) T-Cell Therapy, PD-1/PD-L1 inhibitors, Dendritic Cells, Checkpoint Inhibitors, Adopted Cell Therapy (ACT) & IDO Inhibitors" report to their offering. Cancer immunotherapy drugs have captured nearly 50% of the overall oncology drugs market, generating about $41.0 billion in 2014 alone This report provides a comprehensive overview of the size of cancer immunotherapy market, the segmentation of the market, key players and the vast potential of therapies that are in clinical trials. Oncologic therapeutics cannot cure cancer and yet in 2014, the overall market for cancer therapeutics stood at about $84.3 billion. Any drug that can provide a reasonable survival of more than five years for the cancer patients can achieve a blockbuster status. Within the cancer therapeutics, the immunotherapeutic drugs have gained worldwide acceptance, because they are targeted drugs targeting only the cancer cells. Scope - An overview of cancer immunotherapy that includes: monoclonal antibodies, cancer vaccines and non-specific cancer immunotherapies. - Focus on current trends in cancer immunotherapies that include: anti-PD-1 drugs, Dendritic cell vaccines, T-cell therapies and cancer vaccines. - Insight into the challenges faced by drug developers, particularly about the success vs. failure ratios in developing cancer immunotherapy drugs. - Descriptions about 23 cancer immunotherapeutics approved and used as targeted drugs (some of these products have already been withdrawn from the market). - Insight into the various immunotherapeutics available for specific cancer types. - Description and data for the prevalence of cancer types that are addressed by cancer immunotherapeutics. - Overall global cancer therapeutics market, leading market players and the bestselling cancer drugs. - Detailed account of the market for cancer immunotherapeutics by geography, indication, company and individual drugs. - Profiles, marketed products and products in pipeline of 76 companies that are mostly located in the U.S. and Europe. - Summary table to identify the category of immunotherapy drug offered by the 76 companies. Companies Mentioned - 30 of the 75 Companies Featured - Ablynx NV - Activartis Biotech GmbH - Advaxis Inc. - Aduro BioTech Inc. - Agenus Inc. - AlphaVax Inc. - Amgen Inc. - Antigen Express Inc. - Argos Therapeutics Inc. - Bavarian Nordic A/S - Bellicum Pharmaceuticals Inc. - Biogen Idec Inc.x - Biovest International Inc. - Genmab AS - GlaxoSmithKline - Gliknik Inc. - GlobeImmune Inc. - Heat Biologics Inc. - Immatics Biotechnologies GmbH - ImmunoCellular Therapeutics Ltd. - Merrimack Pharmaceuticals Inc. - Morphotek Inc. - NewLink Genetics Corp. - Northwest Biotherapeutics Inc. - NovaRx Corp. - OncoPep Inc. - Oncothyreon Inc. - OSE Pharma SA - Viventia Biotechnologies Inc. - Wilex AG For more information visit http://www.researchandmarkets.com/research/z6...al_and_usa
HTBX: 7.71 (-0.64), BIIB: 423.57 (+1.46), NWBO: 8.36 (-0.39), ADXS: 22.18 (+0.10), ADRO: 38.17 (-0.50), AMGN: 169.10 (+0.64), GSK: 46.57 (-0.67), ONTY: 1.80 (+0.03), IMUC: 0.53 (+0.02), MACK: 13.44 (+0.18), GBIM: 8.46 (+0.46), ARGS: 8.48 (-0.11), BLCM: 28.55 (+2.59), NLNK: 53.12 (-0.07)
BUYINS.NET: BLCM SqueezeTrigger Price is $23.85. There is $19,639,166 That Short Sellers Still Need To Cover.
M2 - Wed Apr 08, 4:42AM CDT
BUYINS.NET / www.squeezetrigger.com is monitoring BAILIE COMMUNUCATION (NASDAQ:BLCM) in real time and just received an alert that BLCM is crossing above its primary SqueezeTrigger Price, the price that a short squeeze can start in any stock. There are 823100 shares that have been shorted at the volume weighted average SqueezeTrigger Price of $23.85. To access SqueezeTrigger Prices ahead of potential short squeezes beginning, visit http://www.squeezetrigger.com .
BLCM: 28.55 (+2.59)
Another IPO Filed In Hot Cancer Immunotherapy Field
at Investor's Business Daily - Tue Apr 07, 12:55PM CDT
Adaptimmune Therapeutics has filed for an initial public offering, adding another company to one of the hottest sectors in the biotech field. U.K.-based Adaptimmune Therapeutics plans to raise up to $150 million and list on the Nasdaq under the...
BLUE: 136.49 (+1.22), BLCM: 28.55 (+2.59), KITE: 57.56 (-1.43), AMGN: 169.10 (+0.64), JUNO: 55.72 (-0.68)
This Small Biotech Got A Booster Shot On CAR-T Deal
at Investor's Business Daily - Mon Mar 30, 1:15PM CDT
Shares of Intrexon (XON) gapped up on news that the synthetic biotech had formed a collaboration and licensing deal with biopharmaceutical firm Merck KGaA of Darmstadt, Germany, to develop and commercialize CAR-T therapies. Intrexon shares rose 9% to...
ZIOP: 10.88 (+0.03), BLCM: 28.55 (+2.59), KITE: 57.56 (-1.43), MRK: 57.69 (+0.03), CLLS: 31.30 (-0.91), XON: 44.53 (+0.36), AMGN: 169.10 (+0.64), JUNO: 55.72 (-0.68)
Intrexon and Merck Serono team up in cancer immunotherapy
Seeking Alpha - at Seeking Alpha - Mon Mar 30, 8:05AM CDT
BLUE: 136.49 (+1.22), BLCM: 28.55 (+2.59), KITE: 57.56 (-1.43), XON: 44.53 (+0.36), JUNO: 55.72 (-0.68)
IPO Stock Watch: CAR-T Maker Cellectis Slips In Debut
at Investor's Business Daily - Wed Mar 25, 3:59PM CDT
French biotech Cellectis (CLLS) slipped 5.3% in its Nasdaq debut Wednesday to close at 39.30 after enlarging its deal size to $229 million. Cellectis sold 5.5 million shares at $41.50 each, the price being essentially determined by where the stock...
BLCM: 28.55 (+2.59), KITE: 57.56 (-1.43), PFE: 34.93 (+0.04), CLLS: 31.30 (-0.91), JUNO: 55.72 (-0.68)
Bellicum Pharmaceuticals, Inc. (BLCM) in Focus: Stock Jumps 6.1% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Mar 20, 8:18AM CDT
Bellicum Pharmaceuticals, Inc. (BLCM) was a big mover last session, as the company saw its shares rise over 6% on the day.
EARS: 4.65 (-0.75), BLCM: 28.55 (+2.59)
Biotech Stock Mailbag: Breaking the Feuerstein-Ratain Rule; Medical Conferences; Celgene
at The Street - Fri Mar 20, 6:18AM CDT
Biotech columnist Adam Feuerstein answers readers' questions about health care companies.
BIIB: 423.57 (+1.46), ACT: 295.22 (+0.69), OVAS: 29.85 (-0.24), RGLS: 17.40 (-0.22), CTIC: 1.93 (+0.09), CELG: 115.54 (+0.72), BLCM: 28.55 (+2.59), GILD: 104.18 (-1.02), KITE: 57.56 (-1.43), MRK: 57.69 (+0.03), RCPT: 166.76 (-3.37), JUNO: 55.72 (-0.68), NVS: 103.45 (-0.62)
Coronado's Latest Opportunistic Move: CAR-T Therapy
EP Vantage - Seeking Alpha - Thu Mar 19, 2:03PM CDT
Give Coronado Biosciences ’ (NASDAQ: CNDO ) management team top marks for brazen opportunism. After seeing its porcine whipworm egg-based project fail in Crohn's disease, the group is getting into some of biotech's hottest areas, earlier this...
BLCM: 28.55 (+2.59), CNDO: 4.09 (-0.09), CLLS: 31.30 (-0.91)
Juno Therapeutics Comments On Cancer Cure Lifts Group
at Investor's Business Daily - Thu Mar 19, 1:36PM CDT
Enthusiasm about potential cancer cures sent shares of Juno Therapeutics (JUNO) and its peers flying Thursday, though Juno's fourth-quarter earnings late Wednesday missed Wall Street estimates by a lot. "Within the next 12 months, we expect to have...
BLUE: 136.49 (+1.22), BLCM: 28.55 (+2.59), KITE: 57.56 (-1.43), AMGN: 169.10 (+0.64), JUNO: 55.72 (-0.68), NVS: 103.45 (-0.62)
CAR-T cancer therapy stocks head north
Seeking Alpha - at Seeking Alpha - Thu Mar 19, 12:29PM CDT
BLUE: 136.49 (+1.22), ZIOP: 10.88 (+0.03), BLCM: 28.55 (+2.59), KITE: 57.56 (-1.43), CNDO: 4.09 (-0.09), CLLS: 31.30 (-0.91), JUNO: 55.72 (-0.68)
Engineered TCR and CAR Immunotherapeutics Analysis Report 2015
M2 - Thu Mar 19, 12:08PM CDT
Research and Markets (http://www.researchandmarkets.com/research/mvztx7/engineered_tcr) has announced the addition of the "Engineered TCR and CAR Immunotherapeutics 2015" report to their offering. This report Engineered TCR and CAR Immunotherapeutics 2015: A comparative analysis of the landscape of and business opportunities with TCR and CAR antibodies, T cells, NK cells, TILs, DLIs & DLIs as of March 2015 brings you up-to-date regarding key players, key technologies, TCR and CAR immunotherapeutic projects, business deals and private and public financing rounds. The report analyzes the TCR and CAR immunotherapeutic pipelines and stakeholders in the field, especially among Big Pharma/Biotech and technology companies. The report highlights the value of TCR and CAR immunotherapeutics in terms of partnering economic conditions, private financing rounds and (initial) public offerings with the resulting market capitalization of companies. However, progress in clinical trials and supply of clinical grade batches reveals some major limitations which need to be surmounted and the problems solved if TCR and CAR immunotherapeutics want to become commercially viable and successful products. This report describes the challenges and limitations and identifies solutions provided by new technologies which offer tremendous business opportunities. This report has been built in a bottom-up basis by desktop search to identify and describe company, product, technology and business/financing profiles which then are evaluated and analyzed with a final outlook describing perspectives with challenges and opportunities. What will you find in the report? - Profiles of TCR and CAR immunotherapeutics in development - Competitor analysis of CD19 CAR T cells - Options to improve CAR T cells regarding efficacy, safety, manufacturing and commercial value - Target analysis of TCR T cells in R&D - CAR T Cell pipeline in hematology - CAR T Cell pipeline in solid tumors - Allogeneic TCR and CAR T cells in R&D - Universal antibody-targeted CAR T cells and NK cells - Pipeline of most promising TILs, NK cells, DLIs and CTLs - Technologies needed for next generations of TCR and CAR immunotherapeutics - Profiles of biotechnology companies incl. financing and licensing/partnering - Profiles and scope of interest of Big Pharma/Biotech companies for TCRs & CARs - Stakeholder analysis (established, emerging, non-US, technology providing companies) - Potential of alternative adoptive immunotherapies with NK cells, TILs, CTLs and DLIs - Analysis of major partnering deals between Big pharma and technology companies - Economic terms of pharma-biotech deals - Opportunities for biotech-biotech deals in the TCR and CAR field - Potential to raise private money with TCR and CAR technologies - Success in initial public offerings and follow on offerings with TCRs and CARs - Limitations and hurdles with current TCR and CAR immunotherapeutics - Opportunities for novel TCR and CAR immunotherapeutics - Pricing of TCR and CAR immunotherapeutics - Aspects of manufacturing and commercialization Who will benefit from the report? - Venture capital, private equity and investment managers - Financial analysts - CFO - Business development and licensing (BDL) specialists - Marketing managers - CEO, COO and managing directors - Corporate strategy, product and portfolio analysts and managers - Chief Technology Officer - Cell technology and manufacturing specialists - Clinical and preclinical development specialists Key Topics Covered: 1 Introduction 2 Executive Summary 3 Profiles of TCR & CAR Immunotherapeutics, NK Cells, TILs, DLIs and CTLs 4 Pipeline Analysis 5 Technology Companies 6 Pharmaceutical Companies 7 Stakeholder Analysis 8 Selected Technology Profiles 9 Business Perspective on TCR and CAR Immunotherapeutics 10 Outlook for TCR and CAR Immunotherapeutics Companies Mentioned - Adaptimmune - Altor Biosciences - Amgen - Applied Immune Technologies - AstraZeneca - Autolus - Bellicum Pharmaceuticals - Bluebird bio - Cardio3 BioSciences - Celgene - Conkwest - CRISPR Therapeutics - CytomX - Editas Medicine - Eli Lilly - Eureka Therapeutics - GlaxoSmithKline - Immunocore - Intellia Therapeutics - Intrexon - Janssen (J&J) - Juno Therapeutics - Kite Pharma - Lion Biotechnologies - Medigene - Nextera - Novartis - Pfizer - Roche - Servier For more information visit http://www.researchandmarkets.com/research/mv...neered_tcr
BLCM: 28.55 (+2.59), KITE: 57.56 (-1.43), AMGN: 169.10 (+0.64), LBIO: 12.50 (+0.50), JUNO: 55.72 (-0.68), LLY: 72.30 (+0.09), GSK: 46.57 (-0.67), NVS: 103.45 (-0.62), CELGZ: 2.87 (+0.04)
Hot Biotech Juno Therapeutics Burning Through Cash
at Investor's Business Daily - Wed Mar 18, 7:22PM CDT
Juno Therapeutics (JUNO), which set a record as the most highly valued biotech IPO of 2014, reported fourth quarter earnings late Wednesday that missed Wall Street estimates by a wide margin. Juno is developing cellular immunotherapies to treat...
BLCM: 28.55 (+2.59), KITE: 57.56 (-1.43), PFE: 34.93 (+0.04), AMGN: 169.10 (+0.64), JUNO: 55.72 (-0.68)
Medigene AG: Addressing The CAR-T Market Pain Points
Decision Analytics - Seeking Alpha - Wed Mar 18, 11:51AM CDT
I have written about the market opportunity for adoptive cancer immunotherapy before when my interest was piqued by the incredible appreciation of a number of early-stage CAR-T therapy companies (a form of adoptive immunotherapy). Companies such as...
MDVN: 128.88 (+0.29), JNJ: 100.43 (+0.13), ZIOP: 10.88 (+0.03), BLCM: 28.55 (+2.59), KITE: 57.56 (-1.43), JUNO: 55.72 (-0.68), NVS: 103.45 (-0.62)
Cellectis on deck for what should be a very strong IPO
Seeking Alpha - at Seeking Alpha - Wed Mar 18, 9:42AM CDT
BLUE: 136.49 (+1.22), BLCM: 28.55 (+2.59), KITE: 57.56 (-1.43), PFE: 34.93 (+0.04), CLLS: 31.30 (-0.91), JUNO: 55.72 (-0.68)
Bellicum Pharmaceuticals EPS of -$18.99
Seeking Alpha - at Seeking Alpha - Wed Mar 11, 3:12PM CDT
BLCM: 28.55 (+2.59)
